PY
PYXS.US Pyxis Oncology Inc
- Market cap
- USD 169M
- P/E
- -
- P/B
- 4.56x
- ROE
- -221.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PYXS.US undervalued?
Graham numberThe Graham number of Pyxis Oncology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pyxis Oncology Inc fundamental analysis
No fundamental analysis for Pyxis Oncology Inc yet.
Pyxis Oncology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential…
Full company profilePyxis Oncology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pyxis Oncology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.1M | 13.9M | 0.00 |
| Gross Profit | - | -444K | -1.25M | -1.84M | -2.00M | 15.7M | 11.5M | - |
| Operating Income | -2.88M | -12.9M | -69.7M | -123M | -82.2M | -89.5M | -84.4M | -94.5M |
| EBITDA | -2.77M | -12.4M | -75.3M | -123M | -71.9M | -65.5M | -73.7M | -90.8M |
| Net Income | -2.67M | -12.8M | -76.0M | -118M | -73.8M | -77.3M | -79.6M | -91.5M |
| EPS | -0.08 | -0.37 | -2.36 | -3.57 | -1.85 | -1.32 | -1.28 | -1.10 |
| Balance Sheet | ||||||||
| Total Assets | 19.8M | 10.2M | 280M | 211M | 174M | 157M | 91.5M | 76.8M |
| Total Liabilities | 22.7M | 25.8M | 18.7M | 50.6M | 48.0M | 36.4M | 38.1M | 35.5M |
| Shareholders' Equity | -2.87M | -15.6M | 261M | 161M | 126M | 121M | 53.4M | 41.3M |
| Cash & Short-term Investments | 19.7M | 8.08M | 275M | 179M | 119M | 127M | 66.9M | 55.6M |
| Total Debt | 15.0K | 780K | 165K | 18.9M | 21.3M | 20.2M | 18.7M | 17.4M |
| Cash Flow | ||||||||
| Operating Cash Flow | -2.24M | -10.1M | -35.3M | -89.3M | -70.7M | -57.7M | -63.5M | -80.7M |
| Capital Expenditure | 1.48M | 1.48M | 540K | 6.40M | 6.73M | 237K | 9.00K | 0.00 |
| Free Cash Flow | -2.24M | -11.6M | -35.9M | -95.7M | -77.4M | -57.9M | -63.5M | -80.7M |
| Ratios | ||||||||
| ROE | - | - | -29.1% | -73.3% | -58.7% | -64.0% | -149.1% | -221.4% |
| ROA | -13.5% | -126.4% | -27.1% | -55.8% | -42.5% | -49.2% | -87.0% | -119.1% |
| Net Profit Margin | - | - | - | - | - | -478.9% | -574.5% | - |
| Debt to Equity | - | - | 0.00x | 0.12x | 0.17x | 0.17x | 0.35x | 0.42x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pyxis Oncology Inc dividends
Pyxis Oncology Inc has not paid dividends in the last 7 fiscal years.
Who owns Pyxis Oncology Inc
- Insiders 10.08%
- Institutions 66.54%
- Public & others 23.39%
- Shares outstanding 120M
- Free float 62.9M
Top funds holding PYXS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.23M | 2.70% | +100.21% | Sep 2026 |
| iShares Biotechnology ETF | 532K | 0.45% | -0.19% | Oct 2026 |
| HealthInvest Sustainable Healthcare E | 407K | 0.34% | -14.09% | Oct 2026 |
| Fidelity Extended Market Index | 281K | 0.24% | +8.81% | Sep 2026 |
| HealthInvest S&M Cap Healthcare C | 163K | 0.14% | -14.18% | Oct 2026 |
| iShares Micro-Cap ETF | 147K | 0.12% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 123K | 0.10% | +207.74% | Aug 2026 |
| Fidelity Total Market Index | 96.2K | 0.08% | -0.05% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 92.9K | 0.08% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 82.0K | 0.07% | 0.00% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 71.7K | 0.06% | +0.21% | Oct 2026 |
| Vanguard Balanced Index Inv | 53.6K | 0.04% | +99.69% | Sep 2026 |
| Mackenzie GQE US Small Cap F8 | 27.4K | 0.02% | 0.00% | Aug 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 26.7K | 0.02% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 21.2K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 10.4K | 0.01% | -7.29% | Sep 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 10.1K | 0.01% | -0.62% | Jun 2026 |
| Victory Extended Market Index | 7.78K | 0.01% | +30.28% | Sep 2026 |
| Invesco Nasdaq Biotechnology ETF | 6.39K | 0.01% | 0.00% | Oct 2026 |
| ProShares Ultra Nasdaq Biotechnology | 3.33K | 0.00% | 0.00% | Oct 2026 |
Top institutions holding PYXS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| GordonMD Global Investments LP | 10.0M | 8.39% | +143.21% | Jun 2026 |
| Pfizer Inc | 7.03M | 5.89% | 0.00% | Sep 2026 |
| LAURION CAPITAL MANAGEMENT LP | 4.90M | 4.10% | -1.93% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.08M | 1.74% | +2.09% | Jun 2026 |
| BlackRock Inc | 868K | 0.73% | +10.03% | Jun 2026 |
| Palo Alto Investors, LLC | 864K | 0.72% | -14.47% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 831K | 0.70% | +134.34% | Jun 2026 |
| Atle Fund Management AB | 664K | 0.56% | -31.32% | Sep 2026 |
| Geode Capital Management, LLC | 592K | 0.50% | -1.05% | Jun 2026 |
| Woodline Partners LP | 524K | 0.44% | 0.00% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 429K | 0.36% | -7.03% | Jun 2026 |
| Renaissance Technologies Corp | 368K | 0.31% | -52.37% | Sep 2026 |
| Longaeva Partners L.P. | 354K | 0.30% | -29.74% | Jun 2026 |
| Decheng Capital LLC | 327K | 0.27% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 303K | 0.25% | +0.69% | Jun 2026 |
| Jane Street Group LLC | 290K | 0.24% | -4.72% | Jun 2026 |
| State Street Corp | 249K | 0.21% | 0.00% | Jun 2026 |
| Millennium Management LLC | 233K | 0.20% | -41.40% | Jun 2026 |
| UBS Group AG | 155K | 0.13% | -38.92% | Jun 2026 |
| Bank of New York Mellon Corp | 134K | 0.11% | 0.00% | Jun 2026 |
Pyxis Oncology Inc company profile
- Company name
- Pyxis Oncology Inc
- Ticker
- PYXS.US
- Exchange
- USA Stocks
- Listed since
- Oct 8, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 56
- Fiscal year end
- December
- Address
- 321 Harrison Avenue, Boston, MA, United States, 02118
- Phone
- 617 453 3596
- Website
- pyxisoncology.com
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Pyxis Oncology Inc management
10- Mr. Thomas CivikCEO & Chairman · born 1969
- Mr. Jitendra Wadhane C.A., CPAChief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer · born 1980
- Dr. Balu N. Balasubramanian Ph.D.Interim Chief Technology Officer
- Donna RegaladoHead of Human Resources
- Dr. Charles T. Gombar Ph.D.Senior Vice President of Portfolio & Program Management
- Dr. Michael BuiSenior Vice President of Global Regulatory Affairs
- Dr. Supriya Roth Ph.D.Head of Commercial Development
- Dr. Shui He Ph.D.Head of Biometrics
- Dr. Hongwei Wang M.D., Ph.D.Head of ADC Development & Clinical Strategy
- Dr. Marsha Crochiere Ph.D.Head of Translational Medicine & Research